Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Milestone Pharmaceuticals (NASDAQ: MIST) announced its participation in the upcoming Jefferies Healthcare Conference, scheduled for June 3-5, 2025, in New York. The company will be represented by Chief Financial Officer Amit Hasija and Chief Commercial Officer Lorenz Muller. Their presentation is set for June 5th at 8:10 AM EDT.
The presentation will be accessible via webcast and will remain available for replay on Milestone's website for approximately 90 days. Interested parties can find the webcast in the News & Events section at www.milestonepharma.com. Investors seeking meetings with the Milestone team during the conference should contact their Jefferies representative.
Positive
- None.
Negative
- None.
MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the Jefferies Healthcare Conference, to take place June 3 - 5, 2025, in New York.
A webcast of the presentation will be available on June 5th at 8:10 AM EDT. The webcast will be available to watch live and there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com.
If you are interested in meeting with the Milestone team during the conference, please reach out to your Jefferies representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
When is Milestone Pharmaceuticals (MIST) presenting at the Jefferies Healthcare Conference 2025?
Who will represent Milestone Pharmaceuticals (MIST) at the Jefferies Healthcare Conference?
How can I watch Milestone Pharmaceuticals' (MIST) presentation at the Jefferies Conference?
How can investors meet with Milestone Pharmaceuticals' (MIST) management at the Jefferies Conference?
